Sepracor Reports Preliminary Results From A Second Phase III Study For OMNARIS(R) HFA Nasal Aerosol In Seasonal …

Sepracor Inc. announced the preliminary results of a large-scale, 671-patient Phase III study of OMNARIS� (ciclesonide) HFA, an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis (SAR) in adult and adolescent patients. In this study, OMNARIS HFA met its primary efficacy endpoint by demonstrating a statistically significant reduction versus placebo in the …

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • bodytext
  • Bumpzee
  • del.icio.us
  • Facebook
  • Furl
  • Mixx
  • NewsVine
  • Reddit
  • StumbleUpon
  • YahooMyWeb
  • Google

Sepracor Reports Preliminary Results from a Second Phase III Study for OMNARIS� HFA Nasal Aerosol in Seasonal Allergic …

MARLBOROUGH, Mass.—-Sepracor Inc. announced today the preliminary results of a large-scale, 671-patient Phase III study of OMNARIS� HFA, an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis in adult and adolescent patients.

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • bodytext
  • Bumpzee
  • del.icio.us
  • Facebook
  • Furl
  • Mixx
  • NewsVine
  • Reddit
  • StumbleUpon
  • YahooMyWeb
  • Google

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The …

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • bodytext
  • Bumpzee
  • del.icio.us
  • Facebook
  • Furl
  • Mixx
  • NewsVine
  • Reddit
  • StumbleUpon
  • YahooMyWeb
  • Google

TheraQuest launches new analgesic product pipeline

TheraQuest Biosciences, Inc., a clinical stage pain management company today unveiled its analgesic product pipeline. TheraQuest also announced the launch of its new corporate website at http://www.theraquestinc.com.

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • bodytext
  • Bumpzee
  • del.icio.us
  • Facebook
  • Furl
  • Mixx
  • NewsVine
  • Reddit
  • StumbleUpon
  • YahooMyWeb
  • Google

Indoors is no haven for allergy sufferers

As the temperatures begin to sizzle, many Southern California residents are spending more time in the comfort of their air-conditioned homes. But for those with allergies, that may not be such a good thing.

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • bodytext
  • Bumpzee
  • del.icio.us
  • Facebook
  • Furl
  • Mixx
  • NewsVine
  • Reddit
  • StumbleUpon
  • YahooMyWeb
  • Google